Articles
To tweet or not to tweet

To tweet or not to tweet

Rob Walton evaluates the effectiveness of Twitter as a component of the marketing mix. The Twitter CEO, Dick Costello, announced in September that his social networking site had signed up a whopping 100 million active...

Articles
Social pharma faces: Denise Silber

Social pharma faces: Denise Silber

In the latest instalment of social pharma faces we catch up with someone who has played a pivotal role at the interface of pharma, healthcare providers and patients – Denise Silber. We’ve been lucky enough to speak with some fantastic people operating at the forefront of digital and social media pharma engagement during…

Articles
Rare is different: why doctors are often stumped by rare disorders

Rare is different: why doctors are often stumped by rare dis...

In part two of the ‘Rare is different’ series Frieda Hernandez explores how pharma could partner with physicians more effectively for increased diagnoses in patients with rare disorders. There are more than 7,000 rare disorders or “orphan” diseases, each affecting fewer than 200,000 people in the U.S. In Europe, a disease is...

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. FDA nominee Overton dodges questions on Trump influence
  2. Australia starts probe into AI infiltration of Medicare
  3. Lilly forges $3.35bn alliance with China's InnoCare
  4. Telix to buy radiopharma rival ITM for $1.65bn upfront
  5. Advocacy group pokes holes in Trump's MFN pricing claims

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more